Cilastatin: Clinical Trials

4 trials of Cilastatin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 completed, 1 not yet recruiting. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Recruiting 2, Completed 1, Not yet recruiting 1

Follow Cilastatin: new trials by email Literature Review of Cilastatin trials Research Report on Cilastatin

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
"Imipenem/cilastatin" and "Tigecycline", "colistin" and "meropenem" - MDR Bacteria
Phase 2Not yet recruitingAin Shams University602026-04-012026-04-13
Prevention of Nephrotoxin-Induced Acute Kidney Injury Using Cilastatin
Cilastatin Sodium, Placebo-Saline - Acute Kidney Injury
Phase 2RecruitingMatthew James6982025-07-162026-11-13
A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
cilastatine, tiosulfate - Debulking Surgery for Ovarian Cancer, Acute Kidney Injury
Phase 2RecruitingHospital General Universitario Gregorio Marañon902025-02-212025-11-14
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg - Urinary Tract Infections, Pyelonephritis
Phase 2CompletedMerck Sharp & Dohme LLC3022012-05-162019-05-24

Conditions studied

Acute Kidney Injury (2)  ·  Pyelonephritis (1)  ·  Urinary Tract Infections (1)  ·  Urologic Diseases (1)

Sponsors

Ain Shams University (1)  ·  Hospital General Universitario Gregorio Marañon (1)  ·  Matthew James (1)  ·  Merck Sharp & Dohme LLC (1)

Countries

Canada (1)  ·  Egypt (1)  ·  Spain (1)

Top investigators

Matthew T James, MD (1)

Results publications

PMID 28575389